Gout Management in Patients With CKD: A Review

Area of Science:

• Nephrology
• Rheumatology
• Pharmacology

Background:

• Gout management in chronic kidney disease (CKD) presents unique challenges due to medication limitations.
• Traditional dosing for urate-lowering therapies may lead to undertreatment of gout in CKD patients.

Purpose of the Study:

• To review current guidelines and evidence for optimizing gout management in CKD patients.
• To discuss appropriate dose adjustments for urate-lowering therapies beyond standard kidney-dosed limits.
• To explore safety considerations, including allopurinol hypersensitivity syndrome and HLAB*5801 testing.

Main Methods:

• Review of consensus group guidelines on gout management in CKD.
• Literature review of risk factors for allopurinol hypersensitivity syndrome.
• Evaluation of evidence for "start-low-go-low" approach and other management strategies.
• Consideration of kidney transplant recipients and emerging therapies like pegloticase.

Main Results:

• Standard dosing of urate-lowering therapies may be insufficient for gout control in CKD.
• HLAB*5801 allele testing can inform allopurinol use and mitigate hypersensitivity risks.
• The "start-low-go-low" approach offers a strategy for optimizing gout treatment safety and effectiveness in CKD.
• Pegloticase, with immunomodulators, shows potential for refractory gout in CKD.

Conclusions:

• Optimizing gout management in CKD requires individualized treatment plans and consideration of specific dosing strategies.
• Careful patient selection and monitoring are crucial for safe and effective gout treatment in the context of kidney disease.
• Further research into novel therapies and personalized approaches is needed to improve outcomes for CKD patients with gout.